MRI-guided transurethral ultrasound ablation associated with less blood loss, shorter stays, and less pain than robotic prostatectomy.

A new randomized clinical trial found that men with localized, intermediate‑risk prostate cancer recovered faster and ...

– TULSA had no blood loss and no overnight stay, along with reduced post-procedure pain, and more rapid recovery to baseline activities and overall health – The positive perioperative results were ...

– First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment – – TULSA ...

— So far this year alone, 25 TULSA-related scientific research presentations have been delivered at major medical meetings around the world — — Of those, eight (8) presentations were from leading ...

A recent randomized clinical trial has found that men with localized, intermediate-risk prostate cancer recovered faster and ...

(MENAFN- GlobeNewsWire - Nasdaq) TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the“Company”), a commercial-stage medical device company that ...

Traditional surgical and radiological approaches – along with a growing number of emerging technologies – to prostate cancer have made it a controllable disease for many men. At the same time, the ...

TORONTO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...

Profound Medical (PROF) announced the unveiling of its third TULSA-AI software module, UA Alignment Assistant, in addition to six presentations featuring the Transurethral Ultrasound Ablation ...

- First Level 1 study comparing an emerging technology head-to-head with RP in men with prostate cancer - - TULSA had no blood loss and no overnight stay, along with reduced post-procedure pain, and ...

TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, ...